N4 Pharma (STU:0GO) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is N4 Pharma Debt-to-Equity?

N4 Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. N4 Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. N4 Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €1.31 Mil. N4 Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for N4 Pharma's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of N4 Pharma was 0.28. The lowest was 0.28. And the median was 0.28.

STU:0GO's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

N4 Pharma Debt-to-Equity Historical Data

The historical data trend for N4 Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

N4 Pharma Debt-to-Equity Chart

N4 Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

N4 Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of N4 Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, N4 Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

N4 Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, N4 Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where N4 Pharma's Debt-to-Equity falls into.

N4 Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

N4 Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.309
	=	0.00

N4 Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.309
	=	0.00

N4 Pharma (STU:0GO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

N4 Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of N4 Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

N4 Pharma (STU:0GO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » N4 Pharma PLC (STU:0GO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N4P.GB:UK N4P:UK

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.n4pharma.com

N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec.

N4 Pharma (STU:0GO) Headlines

No Headlines